FDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder
GlaxoSmithKline announced that the United States Food and Drug Administration (FDA) granted accelerated approval for Promacta (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The approval is a significant milestone for eltrombopag and the ITP community, as eltrombopag is the first oral thrombopoietin (TPO) receptor agonist approved for adult patients with chronic ITP. GSK expects eltrompopag to be available next week. [more...]
|
|
|
